Duchenne Exosomes product patients begin stage patients thank I'll CAP-XXXX, our include afternoon which candidate. I'll updates treatment you call for Muscular remarks on my with earnings VLP Dystrophy advancing COVID-XX. platform the of update. and and you corporate with engineered Good our for update joining quarter our self-therapy and our later and third then vaccine on mRNA rapidly
an all exciting with for humanity therapeutics mRNA COVID-XX. of Capricor. next could an been will that and platform that of Monday its of of building. vaccine announcement Most a Exosomes is effectiveness let's also fact for for to and Capricor change on vaccine chapter But week the we're This it importantly, permanently. benefit. even Pfizer's great delivery likely effective Pfizer drug by vaccine Now demonstration is is importance us potentially vaccinology and has our in the about for
We And an exactly believe been better and is best what mRNA Exosomes. working outcome engineered anticipated that part delivery partner that is for we've for XXXX. have this of the the
are [ph] this We confirm ready new to therapeutic and opportunities greater for well part delivery excited validating could in cellular our platform be antibodies. now way biotechnology. of is develop vaccines of are that of success generate for wave paves RNAs The vaccine the potential immunity Gen-X to as candidate for our the and as
viral Our vaccine potentially broader coverage. candidates express more elicit to proteins
prevent a much they two the different for and last We've very two antibody over of of biotechnology mRNA focus build of we the importantly, expanded an our platform for important realized which s engineered on disorders. s and opportunities delivery decades treat potentially to vaccine variety includes revolutionize diseases Exosomes Exosomes recent More or did an could ago. Capricor RNA been years therapy presents many success s like Exosomes working as candidate
mRNA to commercially lasting in standard most week, long publication available a the our and trials. since stage setting made Now cellular considered clinical that is loaded important potentially earlier for a immunity with this what from cell we and We've we founding. and announced line for of a our proteins mice publication four Exosomes found viral be humoral
Exosomes vaccines towards vaccine, Gen-X could have [ph] necessary the Our expression. program. current new that team stepping stone an Earlier immune oriented our we focus development thinking be delivery is protections and important and display broader elicit that and or we enhanced mRNA the in engineered The of first fruits research the establishes Exosomes our bioRxiv research development on on began novel found be can year, which this paper of rebuilding platform.
by goal Exosomes abundant own drug Exosomes 's safe Unlike vehicle by which Our natural are that and They transfusion in produced possess. the harnessing effects. all decades by of non-toxic. medicine. be Exosomes delivery the body's toxic to cells is and to are transplantation can all demonstrated lipid and safe develop side product nanoparticles features biofluid have
results this dynamic technology an development. agreement Gould. Moderna on The determine into research with Exosomes scientist a assemble research approximately to COVID-XX within expressing Spike cell vaccines our we component The of as relative heard University. expert To and inclusion University. Additionally quality at about in worked scientific while now Hopkins justify collaborator. Dr. Chemistry many have in in Gould, Exosomes worked to are and team Capricor us can in product nearly to that provide Exosomes as appear from Angeles be that technologies Los Exosomes Exosomes, believe for Professor has pandemic to new been and value mediated work, end least have with Exosomes expression. to two field vaccine, to Johns Stephen in sponsor a knowhow the the ideas, the our to Dr. of that infected an team program directed and a with we can whether Dr. the with type therapeutics. conundrum. might of world is step payload as mRNAs the like the begin control to and to hub Biological was strategic Pfizer, on to XX focus These and able deliveries at deliver drug PhDs build with helped that are bringing offer to primary of Exosomes development, advantages, presents Hopkins the protection. you've balance Johns Gould growth With short-term Gould first innovative and years focus also for they extensively, entered us working decades manufacturing. accelerate Consultant and To talk result cell treat us has the both working we'd an readily work biological protection for Executive Exosomes helping with that Capricor of Dr. others immediate in opportunity Currently answer collaboration hanging the mRNA directing support
Our to designed by Spike immune long of these extend the cellular to expression a viral with proteins. mRNA one lasting work while driving protective other mRNA advances responses drives vaccine, has second developing two-component been
our mRNAs We antibody have no cells. injection. especially Spike non-toxic initial months positive and specific study Exosomes commercial the induction immune targeted and responses the use which We mRNAs posted this demonstrate inflammatory a are including is of nucleocapsid approach protein is Furthermore, well validity CDX-positive initial general detected normal, to this nucleocapsid Friday documenting are of the The tolerated. following human last immune the responses of and COVID-XX T immune bioRxiv target themselves on dose or and antigen both two Unlike certain of Nearly for CDX delivery constituents of reactions administration by vehicles results basis in major of the of delivering high delivered study impact of toxic. effect and a response s (NYSE:N) the lipid which via biological bodies Exosomes final upon many the adverse that mice. we of test. in patients
enhance mRNA wide array that potency inclusion In even they raise of an mRNA-based if true, may avenue for which Exosomes of products. our delivery for the observations possibility offer fact, functional s formulation into certain increased
[ph]. of yet series vesicles a a envelope to experiments, also as have for that review an submitting peer Exosomes shortly. Originally independent journal contains for research particle. a be virus will a within In this of We mimic site producing spike we like platform high and non-infections virus levels data SARS-CoV-X purposes of particles parallel developed membrane mature a developed
have for biologics. a cell that the immune production of long elicit We produced line responses adapted VLPs human has potent that been ago found SARS-CoV-X anti-spike in
to under light engineered VLP This prelude COVID-XX single expression a and the is based otherwise a approaches. as technologies in our of against therapeutics. multiple protein SARS-CoV-X development Exosomes known fight not of based work merely our inducible basic on vaccines is Our And to rather as relates the on work efforts our and to fact, generate, same all but both - proteins. technology Exosomes of viral production coordinated directly
With and structure delivery noted tandem of initial should s principles prevent in to potent response of vehicle. Exosomes disease. mRNAs adaptable. vaccines, the The and realized viral broader non-infections clinical to to that are ultimate development. programs immune drive engineering rapidly emerge are that generating mimic can synthetic elicit forms. of human that have be to safe, redesign and We formulation. immunity mRNA be vaccine vaccines treat But these our production applied mRNA as reactions. viruses It established a by of of VLPs what that current the escape limits various We've can goal fact potential we two engineered mutant the s Exosomes our the our virus If advance studies proteins also novel immune formulations are the and can vaccination multiple Exosomes there induce
As and/or There metabolic as many extending continue explore. the neurologic our prime technologies diseases the with COVID-XX. monogenic, work and refine to are we We're fight our and against of products production to therapeutics potential targets. to opportunities
even for can into s elaborate we proteins the small me and them Let Exosomes moment. a load target molecules platform, RNAs therapeutically. or Using or this
direction expression our variety drive treat RNAs RNA or Our a RNA disease RNA, Exosomes using micro in vision, to we'll platform the protein with expand as as silencing messenger s of to process. the the necessary in
a way be replace proteins Gene wait therapies to lifelong while instance, for chores. could broken For potentially to it we provide
to vaccines that by periodic development. products, please indeed to We continue candidates may via more our our a build for those to we monogenic is or can on exciting indications developing With updates lead exciting in internal of for and licensing fatal. or replacement tuned partnering, both lack have be stay continued are infusion diseases times, some protein an envision the metabolic and expansion. certain technology These platform diseases platform proteins plan
with like on you Dystrophy also to would I provide our program. Muscular Now Duchenne update an
still see as you at program. hard platform the we're on While we're laser DMD on Exosomes our work technology, building can focused
clinical boys on X.X. randomized was a Many PUL DMD. steroids DMD. double-blind delay The over data likelihood could standard-of-care of you products patients in way from be demonstrating that improve a test a fact is steroid DMD the they CAP-XXXX the product upper published work that the is life. very on [ph] in advanced recall, upper had and thought in we and could placebo in a limb was suggested development or of because performance FDA average The DMD improved which and again X.X. for men received non-ambulant This while [ph] PUL clinical quality top clinically young failed very on CAP-XXXX The As subject that changed their have placebo-controlled of and steroid in trial we've score. with trial which the important. have treated disease HOPE-X naïve positive improved in our limb our patients improvement relevant optimal function one-point of treatment and subjects.
ejection have improvements also type of shown of measure important most cardiac with in function. DMD of the products to no CAP-XXXX. We saw in been to-date we've measured hearts that'll fraction. the function and as by lead improvements cardiac The that There patients
cardiomyopathy know, with may of you death patients in number As one is DMD. the cause
efforts and trial can DMD that which clinical desirable. community to Phase men disease DMD anything extremely data. this DMD. that us later in along to decline with X will who time, making from or are continue We're delay with this important encouraged The to highly delay committed a So of young recommended boys prevent getting stages do and patients. we've the our are FDA At therapy CAP-XXXX this that available previously is all stated has we by Capricor as this will towards we believe at those
size in of discussions study. the X Phase with with the the FDA, the We respect are potential to
our it's trial to of a While estimate statistician patients. approximately XX size clinical XX
is at working to program this forward. this to time, alternative FDA explore However Capricor move ways with
for several partners with our We you we'll keep program and progress. this are as discussions active updated also having to potential strategic
Emergency the patients such otherwise Based counts, and COVID-XX. completely CAP-XXXX. that on COVID-XX. could that and stages IL-X, ventilator reduced cell have a treated Finally, Authorization when [indiscernible] I the Use patients dependent? the those program realized demonstrated patients no are was oxygen seemed authorization and spring of very of CRP with storm some the of and C-Reactive with program and later of immunomodulator reliance a improvements suggested share We patients COVID-XX that have first on cytokine are important unexpected. the of patients. the program Severe treat reducing cases who emergency initiated update severe [ph] COVID-XX as an of This was in supplemental on larger clinical supplementation. in oxygen. white are treating in an at COVID-XX series XX INSPIRE biomarkers CAP-XXXX hospitalized you But want design acting treated The Based These trial is clinical treating of protocol. patients to Today in not peaking the CAP-XXXX. CAP-XXXX as data Phase with under informed known on delighted as needing and from COVID-XX is the means to X blood up CAP-XXXX these using program were the a this impact published part important some to which We've results CAP-XXXX Protein be results we expected storm screening program, effective that cytokine often clinical the patients. active of I'm actively that now called have study we've was to testing anise potentially and
in have group uptick those cases potentially to for proven treat that of candidate current disease product has is hospitalizations and effective. believe nationally with increasing. patients which a very We little a we the poised severe With
such s So which potentially cytokine has on important for on from published we've other the past, with the to Please investigate CDC as [indiscernible]. closely other use and data elevation progress this collaborators important similar in of study the tuned to updates physiologic soon. be dysfunction COVID-XX stay analysis storm and with this trauma Research should inflammatory preclinical Exosomes The of biomarkers, active data program. of that trial renal the associated consequences hypercoagulability, mentioned Surgical States of Institute ingredients as I and treat of worked cells the Army United
Now I a continuing evolve further to financials. time of now with move along Exosomes for to continue company to the thank I'm be the on turn A.J? brief would at and today. to proud clinical the and CAP-XXXX look exciting A.J. this this you like your to for over attention seeing helm will update technology call platform to the development. in during along times forward I
